[go: up one dir, main page]

WO2016096685A1 - Traitement pour les stéatoses hépatiques non alcooliques - Google Patents

Traitement pour les stéatoses hépatiques non alcooliques Download PDF

Info

Publication number
WO2016096685A1
WO2016096685A1 PCT/EP2015/079526 EP2015079526W WO2016096685A1 WO 2016096685 A1 WO2016096685 A1 WO 2016096685A1 EP 2015079526 W EP2015079526 W EP 2015079526W WO 2016096685 A1 WO2016096685 A1 WO 2016096685A1
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
tocopherol
acid
treatment
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2015/079526
Other languages
English (en)
Inventor
Szabolcs PETER
Joseph Schwager
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN202210818384.2A priority Critical patent/CN115192568A/zh
Priority to PL15813009.6T priority patent/PL3233074T3/pl
Priority to ES15813009T priority patent/ES2934132T3/es
Priority to US15/536,252 priority patent/US20180000775A1/en
Priority to CN201580073513.8A priority patent/CN107205983A/zh
Priority to JP2017531898A priority patent/JP6750831B2/ja
Priority to KR1020177019245A priority patent/KR20170093966A/ko
Priority to EP15813009.6A priority patent/EP3233074B1/fr
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Priority to BR112017012811-0A priority patent/BR112017012811A2/pt
Publication of WO2016096685A1 publication Critical patent/WO2016096685A1/fr
Anticipated expiration legal-status Critical
Priority to US16/166,357 priority patent/US10682334B2/en
Priority to US16/453,934 priority patent/US11026916B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/18—Lipids
    • A23V2250/186—Fatty acids
    • A23V2250/1882—Polyunsaturated fatty acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/70—Vitamins
    • A23V2250/712—Vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention relates to the use of mixtures of vitamin E and
  • polyunsaturated fatty acids as agents for the prevention, control and/or treatment of conditions associated with excessive fat accumulation in the liver which is not caused by alcohol abuse.
  • PUFAs polyunsaturated fatty acids
  • NAFLD non-alcoholic fatty liver disease
  • NASH non-alcoholic fatty liver disease
  • the present invention relates to the use of such compounds comprising vitamin E and PUFAs as active ingredients in the manufacture of medicaments for the prevention, control and/or treatment of conditions related to NAFLD.
  • the pathophysiology of fatty liver has not yet been fully clarified, a generally accepted mechanism is the "two-hit" theory (Day and James, 1998 Gastroenterology 114:842-845).
  • the first hit corresponds to the accumulation of free fatty acids (FFA) in the liver, which can be related to obesity, or more generally to metabolic syndrome (including diabetes, hypertension and dyslipidemia).
  • the second hit refers to the peroxidation of these fatty acids due to the oxidative stress produced by different factors (Angulo and Lindor, 2001 Gastroenterology 120:1281-1285).
  • the final result of the first hit is an excessive FFA balance, from oversupply and/or failure in lipid beta oxidation, leading to fatty acid accumulation in the liver which gives rise to the first lesions (Charlton et al., 2002 Hepatology 35:898-904). These initial impacts make the liver more vulnerable to aggressive factors of the second hit, which is mediated by oxidative stress and pro- inflammatory cytokines (TNF-a, TGF- ⁇ , IL-6, IL-8).
  • FFAs increase the expression of cytochrome P450 2E1 (CYP 2E1 ), a microsomal enzyme which takes part in the ⁇ -oxidation of several FFAs, causing the release of reactive oxygen metabolites (Weltman et al., 1998 Hepatology 27:128-133). Also some FFAs are metabolized by peroxisomal ⁇ -oxidation, generating additional reactive oxygen metabolites (hydrogen peroxide, hydroxyl radicals) (Rao and Reddy, 2001 Semin Liver Dis 21 :43-55).
  • NF- ⁇ nuclear factor ⁇
  • NF- ⁇ nuclear factor ⁇
  • IL-8 pro-inflammatory cytokines
  • malondialdehyde MDA
  • 4-hydroxynonenal show chemotactic properties and activate pro-inflammatory cytokines (TNF-a, TGF- ⁇ , IL-6, IL-8), and stimulate hepatic collagen-producing stellate cells (Pessayre, 2007 J Gastroenterol Hepatol 22 (Suppl 1 ):S20-S27).
  • NAFLD pro-inflammatory cytokines
  • Patients with NAFLD had an increased expression of TNF-a in the liver (Crespo et al., 2001 Hepatology 34(6): 1158-1163).
  • steatohepatitis characterized by steatosis
  • liver-specific Kupffer cells seem to play an important role in the liver-specific Kupffer cells
  • Kupffer cells are liver- resident macrophages providing significant protection against endotoxins and harmful exogenous particles from the portal vein.
  • the pathogenesis of NASH may encompass hyperendotoxemia (Creely et al., 2007 Am J Physiol Endocrinol Metab. 292:E740-E747) as a consequence of impaired phagocytotic function of Kupffer cells (Lrissada et al., 1998 FASEB J. 12:57-65). Damaged clearance of bacterial metabolites, endotoxins, lipopolysaccharides etc. might speed up the pathogenesis of liver diseases.
  • Kupffer cells Activation of Kupffer cells leads to additional stress stimuli and may determine the fate of hepatocytes from survival toward apoptosis.
  • overproduction of cytokines e.g. TNF-a and IL-16 occurs.
  • Kupffer cells become more sensitive to these molecules (Diehl, 2002 Am J Physiol Gastrointest Liver Physiol. 282:G1 -G5).
  • Inflammatory mediators produced by activated Kupffer cells trigger hepatic stellate cells to synthesize collagen which might result in liver fibrosis and cirrhosis.
  • mediators include e.g. eicosanoids (prostaglandins, leukotrienes), cytokines, chemokines, nuclear factors and/or nitric oxide.
  • the present invention relates to the use of a mixture comprising vitamin E and PUFAs for the treatment, control and/or prevention of hepatic inflammation and cell injury in the liver, more preferably prevention, control and/or treatment of NAFLD and related diseases.
  • the present invention relates to the use of vitamin E and PUFAs in the manufacture of a medicament for the prevention, control and/or treatment of conditions requiring modulation of inflammatory responses in liver cells, in particular the treatment and prevention of NAFLD.
  • Mixtures according to the present invention comprising vitamin E and PUFAs may be used as nutraceutical compositions, i.e. as supplement to dietary
  • compositions i.e., (fortified) food/feed or beverages, or as compositions in dosage unit form such as pharmaceutical compositions, e.g., tablets, granules, pastes or effervescent formulations which may further comprise
  • compositions including, but not limited to, lubricants, colorants, wetting agents, fillers, disintegrants and flavorants.
  • the pastes may be filled into hard or soft gelatine capsules.
  • vitamin E includes both natural and synthetic mixtures of tocopherols, including a-tocopherol, ⁇ -tocopherol, ⁇ -tocopherol and ⁇ -tocopherol.
  • Tocopherol which is liquid at room temperature, is a group of methylated phenolic compounds of the general formula (I),
  • R1 , R3 and R4 are independently from each other hydrogen or methyl groups; and wherein each * represents an individual chiral center.
  • the tocopherols of formula (I) have chiral carbon centers which are indicated by the asterisk (*) in the formula.
  • the configuration at these chiral centers is defined to be either R or S, a concept which is known to the person skilled in the art.
  • the respective tocopherols according to formula (I) exist in 8 different isomers due to these chiral centers (i.e. (2R,4'R,8'R)-, (2R,4'S,8'R)-, (2R,4'R,8'S)-, (2R,4'S,8'S)-, (2S,4'R,8'R)-, (2S,4'S,8'R)-, (2R,4'R,8'S)-, (2R,4'R,8'S)- and (2S,4'S,8'S)-tocopherol).
  • the tocopherols are either present in the form of mixture of said chiral isomers or isomerically pure.
  • the (2RS, 4'RS, 8'RS) tocopherol is also known as (all-rac)- tocopherol.
  • vitamin E is ⁇ -tocopherol which is used in a mixture with PUFA.
  • PUFAs are classified according to the position of the double bonds in the carbon chain of the molecule as n-9, n-6 or n-3 PUFAs.
  • n-6 PUFAs are linoleic acid (C18 : 2), arachidonic acid (C20 : 4), ⁇ -linolenic acid (GL.A, C18 : 13) and dihomo- ⁇ -linolenic acid (DGL.A, C20 : 3).
  • n-3 PUFAs are a- linolenic acid (C18 : 13), eicosapentaenoic acid (EPA, C20 : 5), and
  • DHA docosahexaenoic acid
  • EPA and DHA have attracted interest of the food industry in recent years.
  • the most available sources of these two fatty acids are fish and the marine oils extracted from them or microalgae.
  • PUFAs refers to a fatty acid having a backbone comprising 16 or more carbon atoms, (for example, 16, 18, 20 or 22 carbon atoms (C16, C18, C20, or C22, respectively), and two or more carbon- carbon double bonds in the backbone.
  • a "long-chain PUFA” refers to a fatty acid having a backbone comprising 18 or more carbon atoms, and two or more carbon-carbon double bonds in the backbone, for example, C18:3n-3 (alpha-linolenic acid or ALA).
  • CA:Bn-X When the notation CA:Bn-X is used for a methylene-interrupted PUFA, the "CA" is the number of carbons (for example C18, C20 or C22), B is the number of double bonds and X is the position of the first double bond counted from the methyl end of the fatty acid chain.
  • PUFAs encompass the free acid forms thereof, as well as salts and esters thereof.
  • ester refers to the replacement of the hydrogen in the carboxylic acid group of a PUFA molecule with another substituent. Examples of common esters include methyl, ethyl, trichloroethyl, propyl, butyl, pentyl, tert butyl, benzyl, nitrobenzyl, methoxybenzyl and benzhydryl. Other esters of PUFAs are described in US 2010-0130608 A1 , which is incorporated herein by reference.
  • PUFAs for use with the present invention include omega-3, omega-6, and omega 9 polyunsaturated fatty acids, and oxylipins derived therefrom.
  • Exemplary omega-3 PUFAs for use with the present invention include, but are not limited to, a-linolenic acid (C18:3n-3), C18:4n-4, ⁇ -3 eicosapentaenoic acid (20:5n-3) (eicosapentaenoic acid), ⁇ -3 docosapentaenoic acid (docosapentaenoic acid), ⁇ - 3 docosahexaenoic acid (22:6n-3), docosatetraenoic acid (22:4n-6), and combinations thereof.
  • Exemplary omega-6 PUFAs for use with the present invention include, but are not limited to, ⁇ linolenic acid, linoleic acid, conjugated linoleic acid, arachidonic acid (20:4n-6), ⁇ -6 docosapentaenoic acid, and combinations thereof.
  • a PUFA oil for use with the present invention is all-c/s.
  • the PUFA comprises DHA, also known by its chemical name (all-Z)-4,7,10,13, 16,19-docosahexaenoic acid, as well as any salts or derivatives thereof.
  • DHA encompasses DHA ethyl ester (DHA-EE) as well as DHA free fatty acids, phospholipids, other esters, monoglycerides, diglycerides, and triglycerides containing DHA.
  • DHA is an ⁇ -3 PUFA.
  • the PUFA comprises EPA, known by its chemical name (all-Z)-5,8,1 l,14, 17-eicosapentaenoic acid, as well as any salts or derivatives thereof.
  • EPA encompasses the free acid EPA as well as EPA alkyl esters and triglycerides containing EPA.
  • EPA is an ⁇ -3 PUFA.
  • the PUFA oil that is used to make the thermally stable emulsion is substantially free of one or more specific fatty acids.
  • a PUFA oil that contains DHA-EE can be substantially free of EPA.
  • a PUFA oil that contains EPA-EE can be substantially free of DHA.
  • PUFAs suitable for use with the present invention include, but are not limited to, Martek DHATM S Oil (Martek Biosciences Corp., Columbia, Md.), Rosemary-Free Martek DHATM S Oil (Martek Biosciences Corp., Columbia, Md. ), Microalgae DHATM Oil (Martek Biosciences Corp., Columbia, Md.), OMEGAPURE® oils (Omega Protein Corp., Houston, Tex. ), MARINOL® Oils (Lipid Nutrition, Wormerveer, NL), MEG-3 oils and powders (Ocean Nutrition Corp., Dartmouth, CA), Evogel (Symrise AG, Holzminden, DE), Marine Oil (Arista
  • a particularly useful form of PUFA is ⁇ -3 PUFA which is used in a mixture with vitamin E, in particular a-tocopherol in accordance with the present invention, i.e. for the treatment, control and/or prevention of conditions associated with excessive fat accumulation in the liver which is not caused by alcohol abuse.
  • PUFA's are preferably used in a concentration so that the daily consumption by a human adult (weighing about 70 kg) is in the range of from 10 mg/day to 4000 mg/day, preferably from 200 mg/day to 600 mg/day, more preferably about 400 mg/day.
  • a food or beverage suitably contains about 5 mg to about 1000 mg of a PUFA per serving.
  • the nutraceutical composition is a pharmaceutical formulation such formulation may contain a PUFA in an amount from about 10 mg to about 1000 mg per dosage unit, e.g., per capsule or tablet, or from about 10 mg per daily dose to about 4000 mg per daily dose of a liquid formulation.
  • Vitamin E or its derivative is preferably used in a concentration so that the daily consumption by a human adult (weighing about 70 kg) is in the range of from 5 mg/day to 2000 mg/day, preferably 15 to 50 lU/day, more preferably 30 lU/day.
  • a food or beverage suitably contains about 2 mg to about 500 mg of vitamin E per serving.
  • the nutraceutical composition is a pharmaceutical formulation such formulation may contain vitamin E in an amount from about 5 mg to about 1000 mg per dosage unit, e.g., per capsule or tablet, or from about 5 mg per daily dose to about 2000 mg per daily dose of a liquid formulation.
  • subject as used herein includes, all higher animals wherein
  • inflammatory events are known.
  • a subject is a mammal, including animals or humans.
  • a "fatty liver” or “excessive fat accumulation” associated with NAFDL or NASH means that the liver contains more than about 5 to about 10 wt% of fat.
  • the compounds according to the present invention have hepatoprotective properties and are useful for the prevention, control and/or treatment of conditions involved in NAFLD or related malfunction of the liver. They can also be used as an adjunct to the treatment of a variety of diseases or disorders caused by excessive non-alcoholic fat accumulation in the liver via modulation of biosynthesis/overproduction of inflammatory mediators in the liver cells.
  • the compounds of the present invention are used for the prevention, control and/or treatment of conditions associated with excessive fat accumulation in the liver which is not caused by alcohol abuse, preferably prevention, control and/or treatment of NAFLD and NASH.
  • the present invention is particularly directed to the use of a combination of vitamin E and PUFAs as defined above (in the manufacture of a
  • medicament/composition for the prevention, control and/or treatment of conditions requiring modulation of inflammatory response associated with accumulation of fat in the liver which is not caused by consumption/abuse of alcohol, especially of those conditions mentioned above.
  • compounds/mixtures of the present invention may be used in combination with other nutraceutical compositions or therapeutic agents known to those skilled in the art for treatment, control and/or prevention of inflammatory disorders in the liver by administration prior to, simultaneously with or following the administration of the compound(s) as disclosed herein.
  • compounds/mixtures according to the present invention consist substantially of vitamin E and PUFA - i.e. being the main active ingredients - with furthermore addition of binders, fillers, carriers, excipients including water, glycerol, etc. known to the skilled person.
  • the ratio of vitamin E and polyunsaturated fatty acids which is administered might be in the range of about 1 : 1 to about 1 :5, such as e.g., 1 :2, or in the range of about 4:1 or about 5:1 to about 20: 1 , calculated as weight ratio.
  • the vitamin E is calculated as a- tocopherol.
  • the polyunsaturated fatty acid and vitamin E calculated as a weight ratio of 0.2:1 , 0.4: 1 , 0.6:1 , 1 :1 , 2:1 , 3: 1 , 4: 1 , 5: 1 , 6: 1 , 8:1 , 10:1 , 12:1 , 14: 1 , 16:1 , 18:1 , 20:1 , 25: 1 or 30:1 , wherein the vitamin E is calculated as a-tocopherol.
  • appropriate cells or cell lines i.e. whole blood, macrophages, leukocytes
  • appropriate cells or cell lines i.e. whole blood, macrophages, leukocytes
  • pro-inflammatory prostaglandin E 2 i.e. the product of cyclooxygenase-2
  • nitric oxide synthesized by inducible nitric oxide synthase
  • cytokines and interleukins Due to their anti-inflammatory effects, compounds will reduce the level of the two metabolites.
  • the expression of genes of inflammatory pathways will be monitored by quantitative PCR or by micro-array analysis. Anti-inflammatory compounds reduce their expression levels. Additive and/or synergistic effects of compounds will be identified both at the level of specific inflammatory parameters and more generally in the gene expression profile related to the cellular inflammatory response.
  • the anti-inflammatory effect of a combined therapy with vitamin E and PUFAs can be demonstrated in stimulated macrophages including Kupffer cells by determining the inhibition of the synthesis of cytokines that reflect the inflammatory response.
  • Kupffer cells i.e. liver-resident macrophages
  • a test substance such as mixtures of vitamin E and PUFA according to the present invention.
  • murine macrophages RAW264.7 or even monocyte/macrophages present in peripheral blood cells can be used appropriate surrogate models (Raptis et al. J Hepatology 60, 625-632, 201 ).
  • LPS lipopolysaccharide
  • Vehicle concentrations i.e.
  • DMSO fetal sulfate
  • Culture supernatants may be harvested after appropriate periods of time (e.g. 24 hours).
  • Cytokines and interleukins can be measured by appropriate ELISA-based multiplex assays. The percentage of inhibition of the mentioned inflammatory mediators present in the liver-specific cells at a given
  • concentration of the test substances (compared to maximal production by LPS- stimulated cells) is calculated and the putative synergistic effect of the test substance computed (see below).
  • Example 1 Synergistic effect of vitamin E and PUFA in leucocytes
  • Leukocytes are obtained from healthy donors. Mononuclear cells (MNC) are purified by Ficoll-lsopaque gradient centrifugation. Cells (at 3-8x106 cells/mL) are cultured in phenol-red free RPMI 1640, supplemented with 0.25% FBS, 0.1 mM NEAA, 50 U/mL penicillin, 50 Mg/mL streptomycin and 5x10-5 M 2- mercaptoethanol. Cells are stimulated with LPS (100 ng/mL) and IFN- ⁇ (20 U/mL) for 2-24 h.
  • MNC Mononuclear cells
  • Multiparametric kits for determination of cytokines and chemokines are purchased from BIO-RAD Laboratories (Hercules, CA) and used in the LiquiChip Workstation IS 200 (Qiagen, Hilden, Germany). The data are evaluated with the LiquiChip Analyser software (Qiagen).
  • LPS lipoprotein sulfate suppression protein
  • TNF-alpha inflammatory mediators
  • inflammatory mediators are secreted.
  • IL-1 beta and CCL4/MIP-1 b are also significantly reduced by the two substances (Tables 1 b, 1c).
  • the substances reduces the extent of the inflammatory stress in cells that respond to inflammatory stimuli.
  • a-tocopherol and ⁇ -3 PUFA s are combined at different concentrations and ratios, significant synergistic effects are observed in the inhibition of the production of the pro-inflammatory cytokine TNF-alpha, but also of the pro- inflammatory interleukin IL-1 beta, as well as the chemokine CCL4 (see Tables 1a-c, right column). The synergistic effects are most prominent for TNF-alpha.
  • Table 1 Synergistic effects of a-tocopherol and ⁇ -3 PUFA in the inflammatory response of leukocytes.
  • AT ⁇ -tocopherol; for more details see text.
  • Soft gelatin capsules are prepared by conventional procedures providing a dose of vitamin E of 5 to 1000 mg (e.g. a-tocopherol), such as e.g. 50 mg, and at least one compound selected from the group of PUFAs as defined above of 10 to 1000 mg (e.g. DHA), such as e.g. 200 mg, wherein the amounts are the recommended daily doses.
  • vitamin E e.g. a-tocopherol
  • DHA e.g. 200 mg
  • Other ingredients to be added glycerol. Water, gelatine, vegetable oil.
  • Example 3 Hard gelatin capsules are prepared by conventional procedures providing a dose of vitamin E of 5 to 1000 mg (e.g. ⁇ -tocopherol) and at least one compound selected from the group of PUFAs as defined above of 10 to 1000 mg (e.g. DHA), wherein the amounts are the recommended daily doses.
  • Other ingredients to be added fillers, such as, e.g., lactose or cellulose or cellulose derivatives q.s.; lubricant, such as, e.g., magnesium stearate if necessary (0.5%).
  • Example 4 Tablet
  • Tablets are prepared by conventional procedures providing as active ingredient 5 to 1000 mg of vitamin E (e.g. a-tocopherol), such as e.g. 20 mg, per tablet and at least one compound selected from the group of PUFAs as defined above of 10 to 1000 mg (e.g. DHA), and as excipients microcrystalline cellulose, silicone dioxide (Si02), magnesium stearate, crospovidone NF (which is a disintegratent agent) ad 500 mg.
  • vitamin E e.g. a-tocopherol
  • PUFAs as defined above of 10 to 1000 mg
  • An orange juice drink colored with beta-Carotene 10% CWS and with vitamin E (e.g. ⁇ -tocopherol) and at least one compound selected from the group of PUFAs as defined above (e.g. DHA) may be prepared according to Table 2 and 3.
  • Lemon juice concentrate 45° Brix 173.3 g
  • deionized water is first added to the juice concentrates with gently stirring to allow the juice concentrates to hydrate. Then, the oily flavor and beta-carotene 10% CWS stock solution are added and pre-emulsified in a rotor-stator-homogenizer. Homogenization is performed in a high-pressure homogenizer at 200 bar.
  • Typical serving of a soft drink can be 240 ml, with an amount in Vitamin E (e.g. a-tocopherol) which is about 5-100 mg/serving and an amount in PUFA (e.g. DHA) which is about 5-500 mg/serving
  • Vitamin E e.g. a-tocopherol
  • PUFA e.g. DHA
  • Adherent cells i.e. Kupffer cells
  • Isolation and cultivation is done according to the method described by Li et al.,
  • Immonological Letters 158, 52-56, 2014 or according to any method known in the art are treated with compounds as described above (see Example 1 ). These cells will be activated with an inflammatory stimulus and the effect of substances and combination thereof on the reduction of the inflammatory response is determined. With this set-up, identical effects as those described for blood cell derived macrophages (see Ex. 1 ) are obtained.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne l'utilisation de mélanges de vitamine E et d'acides gras polyinsaturés (AGPI) en tant qu'agents pour la prévention, le contrôle et/ou le traitement d'états associés à l'accumulation excessive de graisse au niveau du foie non provoqués par un abus d'alcool. L'invention concerne la prévention, le contrôle et/ou le traitement, chez le patient le nécessitant, de la stéatose hépatique non alcoolique (NAFLD) et/ou de la stéato-hépatite non alcoolique (NASH). En particulier, la présente invention concerne l'utilisation de tels composés comprenant de la vitamine E et des acides gras polyinsaturés (AGPI) comme principes actifs dans la fabrication de médicaments destinés à la prévention, le contrôle et/ou le traitement de pathologies liées à NAFLD.
PCT/EP2015/079526 2014-12-15 2015-12-14 Traitement pour les stéatoses hépatiques non alcooliques Ceased WO2016096685A1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
KR1020177019245A KR20170093966A (ko) 2014-12-15 2015-12-14 비-알콜성 지방간 질환의 치료
ES15813009T ES2934132T3 (es) 2014-12-15 2015-12-14 Tratamiento para enfermedades de hígado graso no alcohólico
US15/536,252 US20180000775A1 (en) 2014-12-15 2015-12-14 Treatment for non-alcoholic fatty liver diseases
CN201580073513.8A CN107205983A (zh) 2014-12-15 2015-12-14 对非酒精性脂肪肝疾病的新颖治疗
JP2017531898A JP6750831B2 (ja) 2014-12-15 2015-12-14 非アルコール性脂肪性肝疾患の処置
CN202210818384.2A CN115192568A (zh) 2014-12-15 2015-12-14 对非酒精性脂肪肝疾病的新颖治疗
PL15813009.6T PL3233074T3 (pl) 2014-12-15 2015-12-14 Leczenie niealkoholowych stłuszczeniowych chorób wątroby
EP15813009.6A EP3233074B1 (fr) 2014-12-15 2015-12-14 Traitement pour les stéatoses hépatiques non alcooliques
BR112017012811-0A BR112017012811A2 (pt) 2014-12-15 2015-12-14 novo tratamento para doenças hepáticas gordurosas não alcoólicas
US16/166,357 US10682334B2 (en) 2014-12-15 2018-10-22 Treatment for non-alcoholic fatty liver diseases
US16/453,934 US11026916B2 (en) 2014-12-15 2019-06-26 Treatment for non-alcoholic fatty liver diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH19392014 2014-12-15
CH01939/14 2014-12-15

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US15/536,252 A-371-Of-International US20180000775A1 (en) 2014-12-15 2015-12-14 Treatment for non-alcoholic fatty liver diseases
US16/166,357 Continuation-In-Part US10682334B2 (en) 2014-12-15 2018-10-22 Treatment for non-alcoholic fatty liver diseases
US16/453,934 Division US11026916B2 (en) 2014-12-15 2019-06-26 Treatment for non-alcoholic fatty liver diseases

Publications (1)

Publication Number Publication Date
WO2016096685A1 true WO2016096685A1 (fr) 2016-06-23

Family

ID=54884019

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/079526 Ceased WO2016096685A1 (fr) 2014-12-15 2015-12-14 Traitement pour les stéatoses hépatiques non alcooliques

Country Status (9)

Country Link
US (3) US20180000775A1 (fr)
EP (1) EP3233074B1 (fr)
JP (1) JP6750831B2 (fr)
KR (1) KR20170093966A (fr)
CN (2) CN107205983A (fr)
BR (1) BR112017012811A2 (fr)
ES (1) ES2934132T3 (fr)
PL (1) PL3233074T3 (fr)
WO (1) WO2016096685A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020083760A1 (fr) 2018-10-22 2020-04-30 Dsm Ip Assets B.V. Composition présentant une stabilité oxydative améliorée
WO2022049168A1 (fr) * 2020-09-04 2022-03-10 Dsm Ip Assets B.V. 17(s)-hdpa contre des troubles liés au syndrome métabolique

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180000775A1 (en) 2014-12-15 2018-01-04 Dsm Ip Assets B.V. Treatment for non-alcoholic fatty liver diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874603A (en) * 1987-06-06 1989-10-17 Uwe Fratzer Use of vitamin E for normalization of blood coagulation during therapy with high unsaturated fatty acids of omega-3 type
EP0699437A1 (fr) * 1994-08-25 1996-03-06 Prospa B.V. Compositions pharmaceutiques contenants des acides gras polyinsaturés avec des vitamines et provitamines antioxidantes
US20100130608A1 (en) 2008-10-01 2010-05-27 Martek Biosciences Corporation Compositions and methods for reducing triglyceride levels
WO2011097273A1 (fr) * 2010-02-02 2011-08-11 Martek Biosciences Corporation Méthodes et compositions permettant le traitement de la stéatose hépatique non alcoolique au moyen d'acide docosahexaénoïque et de n-acétyl-l-cystéine
EP2740473A1 (fr) * 2012-12-06 2014-06-11 DMF Dietetic Metabolic Food S.R.L. Composition pour le traitement de la mucoviscidose et/ou stéatose hépatique

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101535238A (zh) * 2006-11-01 2009-09-16 普罗诺瓦生物医药挪威公司 作为过氧化物酶体增生物激活受体(PPAR)的活化剂或调节剂的α-取代的ω-3脂质
US10300034B2 (en) 2007-02-22 2019-05-28 Children's Hospital Of Oakland Research Institute Fatty acid formulations and methods of use thereof
WO2009028457A1 (fr) * 2007-08-29 2009-03-05 Shinshu University Agent thérapeutique pour stéatohépatite non alcoolique
CA2790914A1 (fr) * 2010-03-24 2011-09-29 Dong-A Pharm. Co., Ltd. Compositon pharmaceutique comportant un inhibiteur de dipeptidyl peptibase iv pour la prevention ou le traitement de la steatose hepatique non alcoolique et methode de prevention ou traitement de la steatose hepatique non alcoolique a l'aide de celle-ci
WO2014143275A1 (fr) * 2013-03-13 2014-09-18 Matinas Biopharma Inc. Compositions d'acide oméga-3-pentaénoïque et procédés d'utilisation
US20180000775A1 (en) 2014-12-15 2018-01-04 Dsm Ip Assets B.V. Treatment for non-alcoholic fatty liver diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874603A (en) * 1987-06-06 1989-10-17 Uwe Fratzer Use of vitamin E for normalization of blood coagulation during therapy with high unsaturated fatty acids of omega-3 type
EP0699437A1 (fr) * 1994-08-25 1996-03-06 Prospa B.V. Compositions pharmaceutiques contenants des acides gras polyinsaturés avec des vitamines et provitamines antioxidantes
US20100130608A1 (en) 2008-10-01 2010-05-27 Martek Biosciences Corporation Compositions and methods for reducing triglyceride levels
WO2011097273A1 (fr) * 2010-02-02 2011-08-11 Martek Biosciences Corporation Méthodes et compositions permettant le traitement de la stéatose hépatique non alcoolique au moyen d'acide docosahexaénoïque et de n-acétyl-l-cystéine
EP2740473A1 (fr) * 2012-12-06 2014-06-11 DMF Dietetic Metabolic Food S.R.L. Composition pour le traitement de la mucoviscidose et/ou stéatose hépatique

Non-Patent Citations (24)

* Cited by examiner, † Cited by third party
Title
ANGULO, N ENGL J MED, vol. 346, 2002, pages 1221 - 1231
ANGULO; LINDOR, GASTROENTEROLOGY, vol. 120, 2001, pages 1281 - 1285
CHALASANI ET AL., HEPATOLOGY, vol. 55, no. 6, 2012
CHARLTON ET AL., HEPATOLOGY, vol. 35, 2002, pages 898 - 904
CHITTURI; FARRELL, HEPATOLOGY, vol. 36, 2001, pages 403 - 409
CHOU, T-C.; TALALAY, P., A SIMPLE BIOL.CHEM., vol. 252, 1977, pages 6438 - 6442
CHOU, T-C.; TALALAY, P.: "Analysis of combined drug effects - A new look at a very old problem", TRENDS IN BIOLOGICAL SCIENCES., November 1983 (1983-11-01), pages 450 - 454
CREELY ET AL., AM J PHYSIOL ENDOCRINOL METAB., vol. 292, 2007, pages E740 - E747
CRESPO ET AL., HEPATOLOGY, vol. 34, no. 6, 2001, pages 1158 - 1163
DAY; JAMES, GASTROENTEROLOGY, vol. 114, 1998, pages 842 - 845
DIEHL, AM J PHYSIOL GASTROINTEST LIVER PHYSIOL., vol. 282, 2002, pages G1 - G5
GARCIA-MONZON ET AL., J HEPATOL, vol. 33, 2000, pages 716 - 724
LI ET AL., IMMONOLOGICAL LETTERS, vol. 158, 2014, pages 52 - 56
LOFFREDA ET AL., FASEB J., vol. 12, 1998, pages 57 - 65
NEUSCHWANDER-TETRI; CALDWELL, HEPATOLOGY, vol. 37, 2003, pages 1202 - 1219
PACANA ET AL., CURR OPIN CLIN NUTR METAB CARE, vol. 15, 2012, pages 641 - 648
PAPPA ET AL.: "Quantitative combination effects between sulforaphane and 3,3'-generalized equation for the analysis of multiple inhibitions in Michaelis-Menten kinetic systems", J. DIINDOLYLMETHANE ON PROLIFERATION OF HUMAN COLON CANCER CELLS IN VITRO. CARCINOGENESIS, vol. 28, 2007, pages 1471 - 77
PARK ET AL., J GASTROENTEROL HEPATOL, vol. 22, 2007, pages 491 - 497
PATRICK L: "NONALCOHOLIC FATTY LIVER DISEASE: RELATIONSHIP TO INSULIN SENSITIVITY AND OXIDATIVE STRESS. TREATMENT APPROACHES USING VITAMIN E, MAGNESIUM, AND BETAINE", ALTERNATIVE MEDICINE REVIEW, THORNE RESEARCH INC., SANDPOINT, US, vol. 7, no. 4, 1 January 2002 (2002-01-01), pages 276 - 291, XP009067321, ISSN: 1089-5159 *
PESSAYRE, J GASTROENTEROL HEPATOL, vol. 22, no. 1, 2007, pages S20 - S27
RAO; REDDY, SEMIN LIVER DIS, vol. 21, 2001, pages 43 - 55
RAPTIS ET AL., J HEPATOLOGY, vol. 60, 2014, pages 625 - 632
SOLIS HERRUZO ET AL., REV ESP ENFERM DIG, vol. 98, 2006, pages 844 - 874
WELTMAN ET AL., HEPATOLOGY, vol. 27, 1998, pages 128 - 133

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020083760A1 (fr) 2018-10-22 2020-04-30 Dsm Ip Assets B.V. Composition présentant une stabilité oxydative améliorée
WO2022049168A1 (fr) * 2020-09-04 2022-03-10 Dsm Ip Assets B.V. 17(s)-hdpa contre des troubles liés au syndrome métabolique

Also Published As

Publication number Publication date
US20190054063A1 (en) 2019-02-21
JP6750831B2 (ja) 2020-09-02
BR112017012811A2 (pt) 2018-04-10
JP2018500318A (ja) 2018-01-11
EP3233074B1 (fr) 2022-09-28
US11026916B2 (en) 2021-06-08
ES2934132T3 (es) 2023-02-17
US20180000775A1 (en) 2018-01-04
CN107205983A (zh) 2017-09-26
EP3233074A1 (fr) 2017-10-25
CN115192568A (zh) 2022-10-18
PL3233074T3 (pl) 2023-02-06
KR20170093966A (ko) 2017-08-16
US20190314328A1 (en) 2019-10-17
US10682334B2 (en) 2020-06-16

Similar Documents

Publication Publication Date Title
Mazzocchi et al. Bioactive compounds in edible oils and their role in oxidative stress and inflammation
Innes et al. Omega-6 fatty acids and inflammation
Stuchlík et al. Vegetable lipids as components of functional foods
Calder Long-chain n-3 fatty acids and inflammation: potential application in surgical and trauma patients
Jiang Natural forms of vitamin E: metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy
Mischoulon et al. Docosahexanoic acid and ω-3 fatty acids in depression
Serini et al. Dietary n-3 polyunsaturated fatty acids and the paradox of their health benefits and potential harmful effects
Kaur et al. Short-term docosapentaenoic acid (22: 5n-3) supplementation increases tissue docosapentaenoic acid, DHA and EPA concentrations in rats
Carlson et al. The addition of medium-chain triglycerides to a purified fish oil-based diet alters inflammatory profiles in mice
US11026916B2 (en) Treatment for non-alcoholic fatty liver diseases
Stehr et al. Omega-3 fatty acid effects on biochemical indices following cancer surgery
Davanso et al. Impact of dietary fatty acids on macrophage lipid metabolism, signaling and function
DE Lorgeril Essential polyunsaturated fatty acids, inflammation, atherosclerosis and cardiovascular diseases
US11426365B2 (en) Compositions comprising thymoquinone and omega-3 fatty acids
JP2020121972A (ja) Ｎａｆｌｄ治療用組成物
Pizato et al. Ratio of n6 to n-3 fatty acids in the diet affects tumor growth and cachexia in Walker 256 tumor-bearing rats
Aluko Bioactive lipids
JP2016533716A (ja) ステアリドン酸及びオリーブ油を含む食用の脂質組成物
Gauthaman et al. Nutraceutical value of sesame oil
de la Puerta et al. Influence of dietary fat on oxidative stress and inflammation in murine macrophages
Andjic et al. Flaxseed and evening primrose oil slightly affect systolic and diastolic function of isolated heart in male but not in female rats
AU2021249347A1 (en) Composition for improving friendliness and/or empathetic capacity
Calder Lipids and the critically ill patient
Uehara et al. The Importance of Vitamin E
Kiran et al. Nutraceutical properties of dietary lipids

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15813009

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2017531898

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 15536252

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015813009

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20177019245

Country of ref document: KR

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017012811

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112017012811

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170614